Cochrane · systematic review · CD005376
Treatment for IgG and IgA paraproteinaemic neuropathy
Stork, ACJ, Lunn, MPT, Nobile‐Orazio, E, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
2
No studies
2
Included studies
NR
No studies 2 · 50%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Plasma exchange (PE) versus sham exchange for IgG and IgA paraproteinaemic neuropathy
Population: people with IgG and IgA paraproteinaemic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in disability Neuropathy Disability Score Plasma exchange (PE) vs sham exchange | no estimate extracted | 1 study · 18 participants | Low Downgraded: imprecision, indirectness |
Change in sensation using a validated scale (e.g. INCAT sensory sum score) ‐ not measured Plasma exchange (PE) vs sham exchange | no estimate extracted | NR | No studies |
Change in strength Neuropathy Disability Score (weakness) Plasma exchange (PE) vs sham exchange | no estimate extracted | 1 study · 18 participants | Low Downgraded: imprecision, indirectness |
Adverse events ‐ not reported Plasma exchange (PE) vs sham exchange | no estimate extracted | NR | No studies |